Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1314)	7/6/2000 1:37:39 AM
From: nohalo	Read Replies (2) \| Respond to of 52153

Peter: Much as I would like to agree with you (in view of the weighting Biotechs have in my portfolio), I think today's strength in Biotechs amid general tech weakness does not augur an imminent explosion in biotechs. I saw weakness in semis (because of an allegedly poor analyst call), and some bad earnings warnings. I feel that investors, instead of heading for the hills, tried to take refuge in Biotechs, and ran them up. When the market returns to some normalcy soon, I expect to see investors selling biotechs, and get back to some techs. I would be far happier to see the whole tech sector, including Biotechs move up in unison, with the Fed specter of higher interest rates out of the way.